Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Healthcare Advisory Board
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
Cytokine-protein combo may offer treatment for MS
October 21, 2020
Researchers designed a new therapy for multiple sclerosis by fusing a cytokine to a blood protein. In mice, this combination prevented destructive immune cells from infiltrating the central nervous system and decreased the number of cells that play a role in MS development, leading to fewer symptoms and even disease prevention. The results could lead to a new therapy for the disease.
While most immune cells help protect the body from disease, in patients with MS, autoreactive immune cells infiltrate the central nervous system and cause damage. Recent studies have shown Th17 cells – immune cells that are activated in the body's secondary lymphoid organs – migrate to the brain and play a role in the severity of the disease. Several drugs to treat MS work by sequestering these cells in the lymph nodes and preventing them from targeting tissue, but these drugs can have adverse side effects.
Interleukin-4, an anti-inflammatory cytokine, is known to suppress the genes that cause MS and has been found to suppress the reactivation of Th17 cells. To use it as a potential therapy, researchers needed to find a way to keep the IL-4 in the secondary lymphoid organs to ensure that Th17 cells were suppressed and did not migrate.
To do this, researchers at the Pritzker School of Molecular Engineering at the University of Chicago bound IL-4 to a blood protein and injected it into mice that had mouse model of MS and found that it caused the IL-4 to stay within the secondary lymphoid organs. The result was reduced infiltration of Th17 cells into the spinal cord. That suppressed the disease and resulted in fewer symptoms. Researchers found the therapy even prevented MS from developing in the majority of mice they treated with it.
Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the therapy showed few negative side effects, and researchers will next formally study the toxicity of the therapy in hopes of eventually moving it to human clinical trials.
The findings were published in the journal
Nature Biomedical Engineering
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more